DHG Pharmaceutical JSC
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, and dermatology and beauty care products. It also manufactures a… Read more
DHG Pharmaceutical JSC (DHG) - Net Assets
Latest net assets as of December 2025: ₫4.18 Trillion VND
Based on the latest financial reports, DHG Pharmaceutical JSC (DHG) has net assets worth ₫4.18 Trillion VND as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₫5.17 Trillion) and total liabilities (₫983.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₫4.18 Trillion |
| % of Total Assets | 80.97% |
| Annual Growth Rate | 3.63% |
| 5-Year Change | 10.26% |
| 10-Year Change | N/A |
| Growth Volatility | 9.68 |
DHG Pharmaceutical JSC - Net Assets Trend (2019–2025)
This chart illustrates how DHG Pharmaceutical JSC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DHG Pharmaceutical JSC (2019–2025)
The table below shows the annual net assets of DHG Pharmaceutical JSC from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₫4.18 Trillion | +2.14% |
| 2024-12-31 | ₫4.09 Trillion | -15.62% |
| 2023-12-31 | ₫4.85 Trillion | +13.08% |
| 2022-12-31 | ₫4.29 Trillion | +13.14% |
| 2021-12-31 | ₫3.79 Trillion | +6.31% |
| 2020-12-31 | ₫3.57 Trillion | +5.64% |
| 2019-12-31 | ₫3.38 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DHG Pharmaceutical JSC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₫1.51 Trillion | 36.11% |
| Other Components | ₫2.67 Trillion | 63.89% |
| Total Equity | ₫4.18 Trillion | 100.00% |
DHG Pharmaceutical JSC Competitors by Market Cap
The table below lists competitors of DHG Pharmaceutical JSC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sparebank 68 Grader Nord
OL:SB68
|
$29.79 Million |
|
Chung Fu Tex-International Corp
TW:1435
|
$29.81 Million |
|
Stellar Resources Limited
PINK:SLROF
|
$29.82 Million |
|
MAG Holdings Berhad
KLSE:0095
|
$29.82 Million |
|
Torrid Holdings Inc
NYSE:CURV
|
$29.77 Million |
|
Roche Bobois
PA:RBO
|
$29.75 Million |
|
Kyung Nong Corporation
KO:002100
|
$29.75 Million |
|
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
IS:ONCSM
|
$29.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DHG Pharmaceutical JSC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,094,755,097,969 to 4,182,487,185,098, a change of 87,732,087,129 (2.1%).
- Net income of 897,576,116,728 contributed positively to equity growth.
- Dividend payments of 1,307,460,710,000 reduced retained earnings.
- Other factors increased equity by 497,616,680,401.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₫897.58 Billion | +21.46% |
| Dividends Paid | ₫1.31 Trillion | -31.26% |
| Other Changes | ₫497.62 Billion | +11.9% |
| Total Change | ₫- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares DHG Pharmaceutical JSC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.95x to 3.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₫25791.54 | ₫102000.00 | x |
| 2020-12-31 | ₫27258.72 | ₫102000.00 | x |
| 2021-12-31 | ₫28987.56 | ₫102000.00 | x |
| 2022-12-31 | ₫32823.45 | ₫102000.00 | x |
| 2023-12-31 | ₫37117.25 | ₫102000.00 | x |
| 2024-12-31 | ₫31318.38 | ₫102000.00 | x |
| 2025-12-31 | ₫31989.39 | ₫102000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DHG Pharmaceutical JSC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.46%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.04%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.24x
- Recent ROE (21.46%) is above the historical average (20.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.84% | 16.31% | 0.94x | 1.23x | ₫298.17 Billion |
| 2020 | 20.76% | 19.70% | 0.84x | 1.25x | ₫383.48 Billion |
| 2021 | 20.51% | 19.42% | 0.87x | 1.22x | ₫398.22 Billion |
| 2022 | 23.03% | 21.14% | 0.90x | 1.20x | ₫559.30 Billion |
| 2023 | 21.65% | 20.95% | 0.82x | 1.26x | ₫565.37 Billion |
| 2024 | 19.02% | 15.95% | 0.82x | 1.46x | ₫369.44 Billion |
| 2025 | 21.46% | 17.04% | 1.02x | 1.24x | ₫479.33 Billion |
Industry Comparison
This section compares DHG Pharmaceutical JSC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,582,535,610,930
- Average return on equity (ROE) among peers: 15.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DHG Pharmaceutical JSC (DHG) | ₫4.18 Trillion | 18.84% | 0.24x | $29.78 Million |
| Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) | $1.66 Trillion | 16.57% | 0.36x | $182.93 Million |
| DOMESCO Medical Import Export JSC (DMC) | $1.25 Trillion | 18.58% | 0.22x | $22.95K |
| Imexpharm Corp (IMP) | $1.73 Trillion | 12.12% | 0.21x | $117.52 Million |
| Traphaco JSC (TRA) | $1.69 Trillion | 14.81% | 0.39x | $25.67 Million |